Anne has been advising leading pharmaceutical and biotechnology companies for 25 years on both competition law issues and all regulatory aspects related to drugs, chemicals and biologicals, human and veterinary, medical devices, food supplements and cosmetics.
Anne assists clients throughout the product’s life cycle, from R&D to potential market withdrawal and on all regulatory issues faced by health product manufacturers: marketing authorization applications, advertising, social media communication, transparency, patient support programs.
She advises medical device manufacturers and pharmaceutical companies on their market access strategy, particularly for innovative products: early access, transition to marketing authorization and management of the post-early access period, reimbursement strategy and price negotiations with the competent authorities.
Anne has been actively involved in the discussions with key stakeholders and authorities that ultimately led to the legalization of medical cannabis in France. She has been called upon to comment on and propose alternative drafts of the texts during consultations with the authorities.
She also advises entrepreneurs in the medical cannabis sector on shaping their regulatory strategies and aligning their projects with the new regulatory framework, considering the activities they plan to carry out in the French and export markets.
